

## **Agonist Regulation of Muscarinic M<sub>2</sub>/M<sub>3</sub> Receptor Heteromer and M<sub>2</sub> Homomer Stability, but not of the Corresponding M<sub>3</sub> Homomer**

D Aslanoglou, E Alvarez Curto, G Milligan. University of Glasgow, Glasgow, UK

Muscarinic receptors (M<sub>1</sub>-M<sub>5</sub>) belong to class A of the G protein coupled receptor (GPCR) family. There is growing evidence that many GPCRs exist as dimers or higher-order oligomers (1) and muscarinic receptors are no exception (2). Herein, as for the co-existence of homomers and heteromers of the dopamine D<sub>2</sub> and D<sub>3</sub> receptors (3) we demonstrate such combinations of co-expressed human M<sub>2</sub> (hM<sub>2</sub>WT) and a RASSL (Receptor Activated Solely by Synthetic Ligand) form of the human M<sub>3</sub> receptor (hM<sub>3</sub>RASSL) using N-terminal SNAP and CLIP tags in combination with homogeneous time resolved FRET (HTRF) (3). Stable Flp-In<sup>TM</sup> T-REX<sup>TM</sup> 293 cell lines able to inducibly express each of these receptor forms upon addition of doxycycline, and a cell line able to express both hM<sub>3</sub>RASSL constitutively and hM<sub>2</sub>WT in a doxycycline inducible manner were generated.

In these cells both hM<sub>3</sub>RASSL and hM<sub>2</sub>WT were detected after treatment with different concentrations of doxycycline via Western Blots using tag-specific antibodies. Radioligand binding using [<sup>3</sup>H]-QNB indicated that similar amounts of hM<sub>2</sub>WT and hM<sub>3</sub>RASSL were expressed following induction with 5 ng.ml<sup>-1</sup> doxycycline; B<sub>max</sub> (no dox) = 2603 ± 200 fmol.mg protein<sup>-1</sup>; B<sub>max</sub> (+ dox) = 5465 ± 244 fmol.mg protein<sup>-1</sup>). Following induction with doxycycline each of hM<sub>2</sub>WT and hM<sub>3</sub>RASSL homo-oligomers and hM<sub>2</sub>WT-hM<sub>3</sub>RASSL heteromers were identified. Unlike the corresponding homo-oligomers in cells expressing either receptor alone, occupancy of hM<sub>2</sub>WT-hM<sub>3</sub>RASSL heteromers with the hM<sub>2</sub>WT agonist carbachol resulted in a marked, time and concentration-dependent (pIC<sub>50</sub> = 5.2 ± 0.25) decrease in detected heteromers and a concomitant, concentration-dependent (pEC<sub>50</sub> = 5.5 ± 0.2) increase in hM<sub>2</sub>WT homomers. The formation of hM<sub>2</sub>WT-hM<sub>3</sub>RASSL heteromers was significantly decreased (P=0.007) by 1.2 fold in the presence of 1 mM carbachol, and by 1.3 fold when 1 mM carbachol was added in the presence of 100 μM CNO (P=0.037). There was a 2.3 fold increase detected in the hM<sub>2</sub>WT homomers, in the presence of 1mM carbachol (P=0.0002) or 1 mM carbachol and 100 μM CNO together (P=0.001).

Despite the presence of hM<sub>2</sub>WT-hM<sub>3</sub>RASSL heteromers the functional pharmacology of hM<sub>2</sub>WT and hM<sub>3</sub>RASSL receptor specific agonists (carbachol and clozapine N-oxide respectively) were largely unaltered.

1. Milligan G, Mol Pharmacol 84:158, 2013
2. Alvarez-Curto E et al, J Biol Chem 285:23318, 2010
3. Pou C et al, JBC 287:8864, 2012